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SUMMARY
Pheochromocytoma (PCC) is a tumor derived from adrenomedullary chromaffin cells. Prognosis of 
malignant PCC is generally poor due to local recurrence or metastasis. We aim to report a case of 
malignant PCC with 18-year survival and discuss which factors may be related to mortality and long-
term survival in malignant pheochromocytoma. The patient, a 45-year-old man, reported sustained 
arterial hypertension with paroxysmal episodes of tachycardia, associated with head and neck 
burning sensation, and hand and foot tremors. Diagnosis of PCC was established biochemically and 
a tumor with infiltration of renal parenchyma was resected. No genetic mutation or copy number 
variations were identified in SDHB, SDHD, SDHC, MAX and VHL. Over 18 years, tumor progression 
was managed with 131I-MIBG (iodine-metaiodobenzylguanidine) and 177Lutetium-octreotate therapy. 
Currently, the patient is asymptomatic and presents sustained stable disease, despite the presence of 
lung, para-aortic lymph nodes and femoral metastases. Adequate response to treatment with control 
of tumor progression, absence of significant cardiovascular events and other neoplasms, and lack of 
mutations in the main predisposing genes reported so far may be factors possibly associated with 
the prolonged survival in this case. Early diagnosis and life-long follow-up in patients with malignant 
pheochromocytoma are known to be crucial in improving survival. Arch Endocrinol Metab. 2018;62(2):264-9
INTRODUCTION
P heochromocytoma (PCC) is a tumor derived from adrenomedullary chromaffin cells, which produce 
catecholamines, such as norepinephrine, epinephrine 
and dopamine. Approximately 15-20% of chromaffin-
cell tumors arise from extra-adrenal chromaffin cells, 
and they are called paragangliomas (1). PCCs are rare, 
with an incidence of 2 to 8 per 1 million adults, and 
correspond to 5% of all adrenal incidentalomas (2).
The clinical relevance of these tumors is based on 
their potential of secreting cathecolamines, causing 
cardiovascular morbidity and mortality. Around 0.2% to 
1% of patients with hypertension have chromaffin-cell 
tumors. These tumors may also extend into adjacent 
organs, causing mass-effect symptoms (1,2).
Malignant pheochromocytomas are defined as 
those with metastases, evidence of local invasion, or 
recurrence. The main sites of metastasis are lymph 
nodes (80% of patients), bones (50-70%), liver (50%), 
lungs (30-50%), and kidney. Approximately 10% to 
25% of PCCs are malignant (2-4).
There is no available method to accurately predict the 
malignant potential of these tumors when they present 
without metastases. Tumors larger than 5 cm, location of 
the primary lesion, local invasion, tumor necrosis, high 
cellularity, nuclear pleomorphism and hyperchromasia 
are some characteristics that may suggest malignancy, 
but distant metastases remain the only widely accepted 
malignancy criterion (3,5). The pattern of cathecolamine 
secretion is also not useful to differentiate benign from 
malignant pheochromocytomas, despite previous 
reports claiming that dopamine levels may be higher in 
malignant cases (6).
The prognosis of malignant PCC is generally poor 
due to local recurrence or metastasis, with 5-year 
survival rates varying between 40% e 70%, and median 
survival of 7 years (7,8). Nevertheless, there are few 
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more than 15 years after diagnosis (6,8-24). We report 
a case of malignant PCC with 18-year survival and 
discuss which factors may be related to mortality and 
long-term survival in malignant pheochromocytoma. 
CASE REPORT
The patient, a 45-year-old man, reported sustained 
arterial hypertension with paroxysmal episodes of 
tachycardia, associated with burning sensations in the 
head and neck, and hand and foot tremors. On the first 
consultation, blood pressure was 220 x 160 mmHg, 
the heart rate was 58 bpm and a systolic murmur 
2+/6+ in mitral area was noticed, radiating to the left 
sternal border. No relevant family history was reported. 
His father died of prostate cancer at age 65, but there 
were no other cases of cancer in the family.
An abdominal computed tomography (CT) 
scan showed compression of the left kidney by 
a tumor measuring 14.8 x 9.8 cm. At that time 
(1998), the concentrations of total catecholamines 
and vanillylmandelic acid in 24-hour urine sample 
were 1875 μg/24h (normal range: < 100 μg/24h) 
and 86.8 mg/24h (normal range: < 8 mg/24h), 
respectively. Adrenalectomy and nephrectomy were 
performed, accompanied by splenectomy and resection 
of the tail of the pancreas due to tumor infiltration. 
Histopathological examination was consistent with 
pheochromocytoma with vascular invasion and 
infiltration of renal parenchyma.
After two years, the patient presented negative 
biochemical evaluation for pheochromocytoma, 
and the only reported symptom was intestinal 
subocclusion, which was clinically treated. However, 
an abdominal CT scan demonstrated recurrence of a 
tumor measuring 8 x 6 cm, in the left renal bed, which 
was resected. In subsequent years, 131I-MIBG (iodine-
metaiodobenzylguanidine) scintigraphy and abdominal 
and pelvic CT scans showed multiple enlarged para-
aortic lymph nodes, compatible with metastasis, as well 
as metastatic nodules in the left adrenal bed and left 
lung base. Over twelve years, treatment was performed 
with four therapeutic doses of 131I-MIBG (two, seven, 
eleven and thirteen years after the second surgery), 
totaling a cumulative dose of 700 mCi (first dose of 
100 mCi and the others of 200 mCi).
In the last seven years, however, persistently elevated 
levels of urinary normetanephrines have been noted. 
The last magnetic resonance imaging (MRI) revealed 
the presence of node formations on the left para-aortic 
region and on the topography of the ipsilateral adrenal 
gland. Recently, 111Indium-octreotide scintigraphy 
was performed, followed by 177Lutetium-octreotate 
therapy, and the last whole body scan after the second 
therapeutic dose (200 mCi) of 177Lutetium-octreotate 
demonstrated the presence of neuroendocrine lesions 
in the lungs, left para-aortic lymph nodes and in the 
intertrochanteric region of the left femur, suggesting 
active disease (Figure 1). The patient, currently 63 
years old, remains asymptomatic and normotensive, 
under use of antihypertensive medication (Enalapril 
40 mg/day).
In face of the malignant presentation, molecular 
studies were conducted to screen mutations in 
five genes related to pheochromocytoma: SDHB, 
SDHD, SDHC, MAX and VHL. Genomic DNA 
was extracted from 12 mL of EDTA-anticoagulated 
peripheral blood, by the salting out method. All 
coding exons and flanking intronic regions of SDHB, 
SDHD, SDHC, MAX and VHL were amplified and 
automatically sequenced. Since no point mutations 
were found by the Sanger sequencing, analysis 
for large deletions in SDH and VHL was included. 
Multiplex Ligand-Probe Amplification (MLPA) was 
performed using commercially available kits, P226 
for SDH, and P016 for VHL (MRC Holland®). No 
mutation or copy number variations were identified in 
the assessed genes.
Figure 1. 177Lutetium-Octreotate Single-Photon Emission Computed 
Tomography (SPECT) revealing areas of radiopharmaceutical 
hyperconcentration (shown by black arrows) in the lungs (A, axial and 
sagittal view), left para-aortic lymph nodes (B, coronal view), and left 
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DISCUSSION
We report a rare case of malignant pheochromocytoma 
with 18 years of follow-up, during which the patient has 
been asymptomatic and has referred a good quality of 
life after treatment with a cumulative dose of 700 mCi of 
131I-MIBG, followed by 177Lutetium-octreotate therapy. 
While the diagnosis of a malignant pheochromocytoma 
was suspected in 1998 when an invasive 14.8-cm 
adrenal tumor was resected, the confirmation of 
malignancy came with early postoperative evidence 
of locoregional recurrence followed by multiple para-
aortic lymph nodes metastasis. Despite the anatomical 
evidence of relatively stable metastatic disease, no 
evidence of cathecolamine hypersecretion was noted 
for approximately 10 years. Moreover, even though 
urinary normetanephrine levels have slowly increased 
over the last 7 years, the patient remains clinically 
controlled. 
According to recent guidelines, the initial 
diagnosis of pheochromocytoma is based on the 
assessment of increased cathecolamines or metabolites 
(metanephrines) in a plasma sample or in a 24h urine 
collection, followed by localization of the tumor using 
imaging techniques, such as CT, T2-weighted MRI 
and I-MIBG scintigraphy (3). In the present case, MRI 
and I-MIBG scintigraphy have shown complementary 
usefulness in the clinical follow up and identification of 
disease recurrence, as previously reported (25). 
Genetic testing is recommended in all PCC patients, 
since it may guide genetic counselling and ensure 
a personalized approach to patient management. 
Although approximately 14 confirmed genes are 
associated with pheochromocytoma and paraganglioma 
susceptibility, the genes investigated in the present case 
– SDHB, SDHC, SDHD, VHL and MAX – have been 
the main reported genes associated with malignant 
PCC reported so far, according to the Endocrine 
Society Clinical Practice Guideline (1). Metastatic 
disease is one of the features that indicates likelihood of 
a hereditary cause, and it is recommended that patients 
with malignant PCC should undergo genetic testing 
for SDHB, SDHC, SDHD, VHL and MAX (1,26). In 
the presented case, we performed genetic screening 
of those main malignancy predisposing genes, but no 
germline mutations or copy number variations were 
identified. Accordingly, it has been shown that only 40% 
of patients carry germline mutations in the susceptibility 
genes, and up to two thirds of the remaining sporadic 
PCCs have somatic mutations (26).
The prevalence of germline mutations in SDHB, 
SDHC, SDHD, VHL and MAX in PCC and 
paraganglioma patients is, respectively, 10%, 1%, 9%, 
7%, and 1%. SDHx mutations are associated with 
inappropriate activation of hypoxic signaling leading to 
angiogenesis, metabolic alterations and tumorigenesis. 
SDHB mutations are especially related to sporadic 
malignant PCC with poor prognosis, and up to 40% 
of patients with metastatic disease harbor mutations in 
this gene. Hypoxic signaling is also disrupted by loss-of-
function mutations in VHL, which cause von Hippel-
Lindau disease, a syndrome characterized by tumors in 
several organs, including kidney, central nervous system, 
pancreas and adrenal gland. MAX mutations promote 
upregulation of the MYC signaling, a key oncogenic 
pathway, leading to familial pheochromocytomas (1,26).
The absence of germline mutations in the main 
predisposing genes suggests that other mechanisms are 
related to the development of malignancy, particularly 
in indolent cases, which still has no biological markers 
or defined pathophysiological basis. The absence of 
mutations in the reported case, especially SDHB, may also 
be related to long-term survival, since SDHB mutations 
are independently related to shorter survival in patients 
with malignant pheochromocytoma (26). Intriguingly, 
there are few reports of malignant pheochromocytoma 
patients harboring SDHB mutations with prolonged 
survival (17,22). Whether the absence of germline 
mutations in the genes previously associated with 
a malignant behavior represents a protective factor 
against aggressive disease must be further investigated. 
Curative treatment for malignant PCC is not available 
yet, and surgery is focused on reducing hormonal 
activity and palliating local complications. MIBG-
radiotherapy, radiolabeled somatostatin analogues 
(e.g. octreotide), and chemotherapy are other available 
therapeutic options. Conventional chemotherapeutic 
regimens (e.g. cyclophosphamide, vincristine, and 
dacarbazine) provide limited efficacy (27).
Several studies have investigated the use of 
radiolabeled MIBG for treatment of malignant PCC. 
Dose regimen and tumor response are variable, as 
there is no established agreed-upon protocol. A 
phase II study involving 50 patients with malignant 
pheochromocytoma or paraganglioma treated with 
high-dose 131I-MIBG showed overall 5-year survival 
rate of 64% and sustained stable disease in 8% of patients 
(28). Another study reported median survival of 4.7 
years for patients with malignant PCC after treatment 
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1 43 Adrenal Uni NA Pleura NA 20 Traub and Rosenfeld (1970) (9)
2 NA NA NA NA NA 17
Remine and cols. (1975) (10)
3 NA NA NA NA NA 20
4 NA NA NA NA NA 20
5 NA NA NA NA NA 21
6 NA NA NA Lung NA 25
Van den Broek and De Graeff 
(1978) (11)
7 7 Adrenal Uni NA Left renal hilus NA 21 Abemayor and cols. (1980) (12)
8 NA NA NA NA NA >20 Brennan and Kaiser
(1982) (13)9 NA NA NA NA NA 23
10 NA NA NA Liver NA 17 Okada and cols. (1990) (14)
11 NA NA NA NA NA 22 Mornex and cols. (1992) (15)
12 44 Adrenal Uni NA
Lumbar vertebrae and 
ilium
NA 26 Yoshida and cols. (2001) (16)
13 32 Extra-adrenal NA Liver and vena cava SDHB 30 Young and cols. (2002) (17)
14 NA NA NA Bone NA 30
Arias Martinez and cols. (2003) 
(24)
15 19 Adrenal Bi NA Liver NA 29 Mózes and cols. (2003) (18)
In the present case, the patient responded to 
treatment with 131I-MIBG for 12 years and, more 
recently, to 177Lutetium-octreotate therapy. Currently, 
the patient presents sustained stable disease, despite the 
presence of metastases in the lung, para-aortic lymph 
nodes and, more recently, femoral metastasis. Repeated 
intermediate-dosage of 131I-MIBG is considered an 
efficient and well-tolerated treatment in patients with 
malignant PCC, but the role of 131I-MIBG in longevity 
remains to be elucidated in patients with long-term 
survival (19).
The most frequent cause of death in malignant 
pheochromocytoma is tumor progression, highlighting 
the importance of controlling tumor growth in disease 
management. Cardiovascular manifestations related 
to catecholamine hypersecretion account for 30% of 
mortality (4). The main cardiovascular events associated 
with mortality are myocardial infarction, heart failure, 
cerebrovascular complications, and hypertensive 
or hypotensive crisis associated with operations for 
unrelated conditions (7). 
Other cancers are also associated with mortality in 
PCC. These additional neoplasms may occur in the 
context of genetic syndromes, such as von Hippel-
Lindau syndrome and neurofibromatosis type 1. They 
also may be sporadic, considering that presence of 
pheochromocytoma is associated with increased risk of 
developing other malignancies (melanoma, carcinoma 
of uterine cervix, liver/biliary tract and central nervous 
system tumors) (30). So far, no additional or secondary 
neoplasm has been identified in our case. Control of 
tumor progression, as well as the absence of significant 
cardiovascular events and other cancers may have 
contributed to the prolonged survival in the reported case. 
An extensive literature search from 1970 to 2016 
revealed 42 cases of malignant pheochromocytomas 
and paragangliomas with more than 15 years of survival 
(Table 1). It is noteworthy that a significant number 
of malignant cases with prolonged survival (11 of 42; 
26%) were described more than 25 years ago, when 
imaging and radionuclide-based therapies were not 
widely available in clinical practice. Overall, among 
31 cases of malignant PCCs with prolonged survival 
in which the primary tumor localization was provided, 
the majority were unilateral adrenal tumors (62.5%; n 
= 20), followed by extra-adrenal (35.5%; n = 11), and 
bilateral tumors (3.2%; n = 1). Only two studies (17,22) 
performed genetic analysis, and out of four cases in 
which genetic screening was performed in apparently 
sporadic malignant PCC, three presented SDHB 
mutations, and one patient was negative for SDHB, 
SDHD, RET and VHL mutations. The variability in 
clinical presentation and rarity of cases with prolonged 
survival impair the establishment of definitive factors 
associated with better outcomes and long-term survival 
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16 43 Adrenal Uni 9
Liver and 
retroperitoneum
NA 16 Lam and cols. (2005) (19)
17 18 Extra-adrenal NA Bone NA 21
Sisson and cols. (2006) (20)
18 30 Adrenal Uni NA Lung NA 34
19 17 Extra-adrenal NA Regional NA 25
20 25 Adrenal Uni NA Liver NA 17
21 39 Adrenal Uni NA Liver NA 17
22 42 Adrenal Uni NA Regional NA 18
23 23 Adrenal Uni NA Liver NA 36
24 10 Extra-adrenal NA Bone NA 32
25 36 Adrenal Uni NA Lung NA 17
26 69 Extra-adrenal NA Liver NA 16
27 15 Adrenal Uni NA Bone NA 45
28 51 Adrenal Uni 11x12x11 Lung and bone NA 20 Huang and cols. (2007) (6)
29 34 Adrenal Uni 22 NA NA 18 Szalat and cols. (2011) (21)
30 49 Adrenal Uni NA Lung NA 19
Choi and cols. (2015) (8)




32 26 Adrenal Uni NA Lung NA 18
33 14 Adrenal Uni NA
Liver, lung, duodenum, 
bone
NA 25
34 47 Extra-adrenal NA NA NA 17
Rutherford and cols. (2015) (22)
35 50 Extra-adrenal NA NA NA 25
36 15 Extra-adrenal NA NA NA 21
37 26 Adrenal Uni NA NA NA 31
38 56 Adrenal Uni NA NA SDHB 16
39 13 Extra-adrenal NA NA SDHB 25
40 31 Adrenal Uni NA NA Negative 18
41 32 Extra-adrenal NA NA NA 26
42 53 Extra-adrenal NA Anterior cranial fossa 
and cervical lymph 
nodes
NA 22 Belgioia and cols. (2016) (23)
Uni: unilateral; Bi: bilateral; NA: not available.
This case report and literature review carefully 
illustrate that regular clinical monitoring with 
imaging and biochemical evaluation of malignant 
pheochromocytomas is essential to address tumor 
behavior, and to ensure prompt intervention when 
complications or tumor recurrence arise. In addition, 
early diagnosis and life-long follow-up are crucial for 
improving survival. Adequate response to treatment 
with control of tumor progression, absence of significant 
cardiovascular events and other neoplasms, and lack of 
mutations in the main predisposing genes reported so 
far might be associated with the prolonged survival in 
the presented case. Further studies involving a larger 
number of cases are needed to compare the clinical, 
biochemical and molecular signatures of malignant 
pheochromocytomas with indolent versus aggressive 
behavior and treatment response. 
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